Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Výzkumná studie u dětí, které se narodily malé a které malé zůstaly. Léčba je Somapacitan jednou týdně ve srovnání s Norditropinem® jednou denně

5. října 2026 aktualizováno: Novo Nordisk A/S

Studie zaměřená na zjištění dávky hodnotící účinek a bezpečnost léčby somapacitanem jednou týdně ve srovnání s denním Norditropinem® u dětí s nízkým vzrůstem narozeným malým vzhledem ke gestačnímu věku bez dohánění růstu do 2 let věku nebo starších

The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).

Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.

Přehled studie

Postavení

Aktivní, ne nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

62

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Algiers, Alžírsko, 16000
        • CHU Bab El Oued Pediatrics Dept
      • Algiers, Alžírsko, 16000
        • Endo and Diab Dept El Oued
      • Constantine, Alžírsko, 25000
        • endocrino-diabetology department, Hospital IBN BADIS.
      • Copenhagen Ø, Dánsko, 2100
        • Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064
      • Tallinn, Estonsko, 13419
        • Tallinn Children's Hospital
      • Tartu, Estonsko, 50406
        • Tartu University Hospital Children's Clinic
      • Angers, Francie, 49100
        • Centre Hospitalier Universitaire D'Angers-2
      • Le Kremlin-Bicêtre, Francie, 94270
        • AP-HP-HOPITAL DE BICETRE_Service d'Endocrinologie pédiatrique
      • Marseille, Francie, 13005
        • Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
      • Marseille Cédex 05, Francie, 13385
        • Hopital de La Timone
      • Paris, Francie, 75015
        • Ap-Hp-Hopital Necker
      • Paris, Francie, 75015
        • Hôpital Necker
      • Toulouse, Francie, 31059
        • HOPITAL DES ENFANTS-HOPITAL PAULE DE VIGUIER - Pharmacie
    • Kerala
      • Kochi, Kerala, Indie, 682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Maharashtra
      • Pune, Maharashtra, Indie, 411001
        • Jehangir Clinical Development Centre
    • New Delhi
      • New Dehli, New Delhi, Indie, 110029
        • All India Institute of Medical Sciences
      • Dublin, Irsko, D12 N512
        • CHI Crumlin Dept of Endocrinology
      • Florence, Itálie, 50139
        • IRCCS Meyer Firenze
      • Genova, Itálie, 16147
        • Ospedale Pediatrico Gaslini
      • Milan, Itálie, 20122
        • Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
      • Roma, Itálie, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Haifa, Izrael, 31096
        • Rambam MC - Department of Pediatrics A
      • Kfar Saba, Izrael, 44281
        • Meir MC - Department of Paediatrics
      • Petah Tikva, Izrael, 49202
        • Schneider MC - Endrocrinology and Diabetes
      • Fukuoka, Japonsko, 830-0011
        • Kurume University Hospital, Pediatrics
      • Fukuoka-shi, Fukuoka, Japonsko, 813-0017
        • Fukuoka Children's Hospital_Endocrinology and Metabolism
      • Fukuoka-shi, Fukuoka, Japonsko, 813-0017
        • Fukuoka Children's Hospital
      • Fukuyama-shi, Hiroshima, Japonsko, 721-8511
        • Fukuyama City Hospital_Department of Pediatrics
      • Kobe-shi, Hyogo, Japonsko, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
      • Kobe-shi, Hyogo, Japonsko, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital_Metab & endo
      • Kyoto, Japonsko, 602-8566
        • Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
      • Nara-shi, Nara, Japonsko, 630-8581
        • Nara Prefecture General Medical Center_ Nara-shi, Nara
      • Nara-shi, Nara, Japonsko, 630-8581
        • Nara Prefecture General Medical Center_Pediatric
      • Niigata-shi, Niigata, Japonsko, 951 8520
        • Niigata University Medical & Dental Hospital_Pediatrics
      • Osaka, Japonsko, 534-0021
        • Osaka City General Hospital, Pediatric Endocrinology and Me
      • Osaka, Japonsko, 594-1101
        • Osaka Women's and Children's Hospital
      • Saitama-shi, Saitama, Japonsko, 330-8777
        • Saitama Children's Medical Center, Endocrinorogy&Metabolism
      • Tokyo, Japonsko, 157 8535
        • National Center for Child Health and Dev, Endo and Metabo
      • Tokyo, Japonsko, 113-8519
        • Institute of Science Tokyo Hospital
      • Tokyo, Japonsko, 113-8519
        • Institute of Science Tokyo Hospital_Pediatrics
      • Tokyo, Japonsko, 157 8535
        • National Center for Child Health and Development_Endo and Metabo
      • Tokyo, Japonsko, 160-8582
        • Keio University Hospital_Pediatrics
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2B7
        • Stollery Children's Hospital
      • Riga, Lotyšsko, 1004
        • Children's Clinical University Hospital
      • Budapest, Maďarsko, 1023
        • Észak-Közép-budai Centrum, Szent János Kórház és Szakrendelő
      • Szeged, Maďarsko, 6720
        • Szegedi Tudományegyetem Gyermekgyógyászati Klinika
      • Bergen, Norsko, 5021
        • Haukeland Universitetssykehus, Barneklinikken
      • Szczecin, Polsko, 71-252
        • SPSK nr 1 im Prof. T Sokolowskiego
      • Warsaw, Polsko, 04-730
        • Instytut ''Pomnik - Centrum Zdrowia Dziecka''
      • Graz, Rakousko, 8036
        • Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
      • Salzburg, Rakousko, A 5020
        • LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
      • Sankt Pölten, Rakousko, 3100
        • LKH St. Poelten, Kinder-und Jugendheilkunde
      • Vöcklabruck, Rakousko, 4840
        • Salzkammergut-Klinikum Vöcklabruck
    • Upper Austria
      • Linz, Upper Austria, Rakousko, 4020
        • Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)
      • Izhevsk, Rusko, 426009
        • Republic Children's Hospital of Ministry of Health of Udmurt
      • Moscow, Rusko, 119435
        • Setchenov First Moscow State Medical University
      • Moscow, Rusko, 125373
        • RMAPE
      • Novosibirsk, Rusko, 630048
        • Children's clinical city hospital #1
      • Rostov-on-Don, Rusko, 344013
        • FSBEI of Higher Education "Rostov State Medical University"
      • Saint Petersburg, Rusko, 191144
        • SPSBHI City Children out-patient clinic #44
      • Samara, Rusko, 443079
        • Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
      • Tomsk, Rusko, 634050
        • Siberian State Medical University
      • Hull, Spojené království, HU3 2JZ
        • Hull Royal Infirmary
      • Liverpool, Spojené království, L12 2AP
        • Alder Hey Children's Hospital
      • London, Spojené království, E1 1BB
        • Royal London Hospital_London
      • Manchester, Spojené království, M13 9WL
        • Royal Manchester Children's Hospital
    • Alabama
      • Birmingham, Alabama, Spojené státy, 35233
        • Univ of AL at Birmingham_BRM
    • California
      • Orange, California, Spojené státy, 92868
        • Children's Hosp Of Orange
    • Idaho
      • Boise, Idaho, Spojené státy, 83712
        • St. Luke's Children's Endo
    • Minnesota
      • Minneapolis, Minnesota, Spojené státy, 55454
        • Univ of Minnesota M.C.H.
      • Saint Paul, Minnesota, Spojené státy, 55102
        • Children's Minnesota
    • New Jersey
      • Morristown, New Jersey, Spojené státy, 07962
        • Goryeb Children's Hospital
      • New Brunswick, New Jersey, Spojené státy, 08901
        • Rutgers-Rwjms
    • New York
      • Garden City, New York, Spojené státy, 11530
        • NYU Langone Hospital-LI
      • Mineola, New York, Spojené státy, 11501
        • NYU Langone Hospital-LI
      • New York, New York, Spojené státy, 10029
        • Icahn Sch of Med-Mt Sinai Hosp
    • Ohio
      • Cincinnati, Ohio, Spojené státy, 45229
        • CCHMC_Cinc
    • Oklahoma
      • Oklahoma City, Oklahoma, Spojené státy, 73104
        • Univ Oklahoma Sci Ctr OK City
    • Texas
      • Fort Worth, Texas, Spojené státy, 76104
        • Cook Children's Hospital-Hematology-Oncology
    • Washington
      • Tacoma, Washington, Spojené státy, 98405
        • MultiCare Inst for Res & Innov
      • Belgrade, Srbsko, 11000
        • University Children's Hospital Tirsova
      • Belgrade, Srbsko, 11070
        • Institute for Mother and Child Health Care of Serbia
      • Kragujevac, Srbsko, 34000
        • University Clinical Centre Kragujevac
      • Niš, Srbsko, 18 000
        • Clinical Center in Nis
      • Novi Sad, Srbsko, 21000
        • Institute for Health Care of Children and Adolescents
      • Bangkok, Thajsko, 10330
        • King Chulalongkorn Memorial hospital-Ped-Endocrinology
      • Bangkok, Thajsko, 10330
        • King Chulalongkorn Memorial hospital_Ped-Endocrinology
      • Bangkok, Thajsko, 10400
        • Phramongkutklao Hospital_Ped-Endo_Pediatrics
      • Dnipro, Ukrajina, 49100
        • Dnipropetrovsk Regional Children's Clinical Hospital - Endocrinology department
      • Kharkiv, Ukrajina, 61093
        • Kharkiv Regional Children's Clinical Hospital - Endocrinological department
      • Kyiv, Ukrajina, 04114
        • Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
      • Esplugues Llobregat(Barcelona), Španělsko, 08950
        • Hospital Sant Joan de Déu
      • Santiago de Compostela, Španělsko, 15706
        • Hospital Clínico de Santiago de Compostela
      • Bern, Švýcarsko, 3010
        • Med. Kinder- und Poliklinik
      • Zurich, Švýcarsko, 8032
        • Kinderspital Endokrinologie, Zürich

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

2 roky až 11 let (Dítě)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Pre-pubertal children, boys:

    1. age between 2.5 and 11.0 years at screening.
    2. testes volume below 4 ml.
  • Pre-pubertal children, girls:

    1. age between 2.5 and 10.0 years at screening.
    2. Tanner stage 1 for breast development (no palpable glandular breast tissue).
  • Born small for gestational age (birth length and/or weight below -2 standard deviation scores) (according to national standards).

  • Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and gender at screening according to the standards of Centers for Disease Control and Prevention at screening.

  • Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.

  • No prior exposure to growth hormone therapy or Insulin-like Growth Factor-I (IGF-I) treatment.

Exclusion Criteria:

  • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements.
  • Children with hormonal deficiencies including suspected or confirmed growth hormone deficiency according to local practise.
  • Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
  • Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening.
  • Concomitant administration of other treatments that may have an effect on growth, e.g but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder.
  • Diagnosis of attention deficit hyperactivity disorder.
  • Prior history or presence of malignancy including intracranial tumours.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Somapacitan 0.24 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Experimentální: Somapacitan 0.20 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Experimentální: Somapacitan 0.16 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Aktivní komparátor: Norditropin® 0.035 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Aktivní komparátor: Norditropin® 0.067 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Height Velocity
Časové okno: Baseline (week 0); week 26

Height velocity (HV) was derived from height measurements taken at baseline (week 0) and week 26 visit as: HV = (height at 26 weeks visit - height at baseline)/(time from baseline to 26 weeks visit in years). The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Ratio of Bone Age Versus Chronological Age
Časové okno: Baseline (week 0); week 52

Change in ratio of bone age (years) versus chronological age (years) from baseline (week 0) to week 52 is presented. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. X-ray images were sent to a central imaging laboratory for evaluation. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 52 or last trial contact, whichever came first.

Baseline (week 0); week 52
Change in Height Standard Deviation Score (HSDS)
Časové okno: Baseline (week 0); week 26

Change in HSDS from baseline (week 0) to week 26 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. HSDS = [(height/population median)^skewness - 1]/(skewness * population standard deviation) where skewness, median and standard deviation is given by a reference growth table for the corresponding chronological age. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Height Velocity Standard Deviation Score (HVSDS)
Časové okno: Baseline (week 0); week 26

Change in HVSDS from baseline (week 0) to week 26 is presented. HVSDS was derived using Prader standards. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HVSDS indicated that HVSDS was better than baseline HVSDS. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Fasting Plasma Glucose
Časové okno: Baseline (week 0); week 26

Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Steady State Beta Cell Function (HOMA-B)
Časové okno: Baseline (week 0); week 26

Change in HOMA-B from baseline (week 0) to week 26 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). HOMA-beta score ranges from minus infinity to infinity (no limits). Higher score means better beta-cell function for HOMA-beta. Negative change from baseline (week 0) in HOMA-B indicated a worse outcome. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Časové okno: Baseline (week 0); week 26

Change in HOMA-IR from baseline (week 0) to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a participant's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered insulin sensitive, 0.5-1.4: considered healthy, above 1.8: considered early insulin resistance; above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Glycated Haemoglobin (HbA1c)
Časové okno: Baseline (week 0); week 26

Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS)
Časové okno: Baseline (week 0); week 26

Change in IGF-I SDS from baseline (week 0) to week 26 is presented. IGF-I SDS was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. Positive value in change from baseline in IGF-I SDS indicated that IGF-I SDS was higher than baseline IGF-I SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) SDS
Časové okno: Baseline (week 0); week 26

Change in IGFBP-3 SDS from baseline (week 0) to week 26 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. Positive value in change from baseline in IGFBP-3 SDS indicated that IGFBP-3 SDS was higher than baseline IGFBP-3 SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Ředitel studie: Clinical Reporting Anchor and Disclosure 1452, Novo Nordisk A/S

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

4. července 2019

Primární dokončení (Aktuální)

5. května 2021

Dokončení studie (Odhadovaný)

23. prosince 2026

Termíny zápisu do studia

První předloženo

15. března 2019

První předloženo, které splnilo kritéria kontroly kvality

15. března 2019

První zveřejněno (Aktuální)

18. března 2019

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

6. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

5. října 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • NN8640-4245
  • 2018 (Grant/smlouva NIH USA)
  • U1111-1207-9741 (Jiný identifikátor: World Health Organization (WHO))
  • 2018-000232-10 (Číslo EudraCT)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .